We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
OptimizeRX (OPRX - Free Report) is a Zacks Rank #1 (Strong Buy) that has an F for Value and an A for Growth. The company runs a health solutions platform that helps physicians and patients better afford and comply with their medicines and healthcare products. The company is expected to report earnings on 8/7, so now is a great time to take a look at this small cap company. Let’s learn more about why this stock is the Bull of the Day.
Description
OptimizeRx Corporation provides consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. It offers pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. The Company offers marketing and advertising solutions by connecting patients, physicians, and pharmaceutical manufacturers through its consumer Websites. OptimizeRx Corporation is based in Rochester, Michigan.
Earnings History
When I look at a stock, the first thing I do is look to see if the company is beating the number. This tells me right away where the market’s expectations have been for the company and how management has communicated to the market. A stock that consistently beats has management communicating expectations to Wall Street that can be achieved. That is what you want to see.
OptimizeRX (OPRX - Free Report) has posted four consecutive beats of the Zacks Consensus Estimate. The takeaway from the earnings history is that the company has an average positive earnings surprise of 105% over the last year.
The most recent earnings print saw the company post $0.08 when the consensus was at -$0.11. That 19 cent beat translates into a positive earnings surprise of 172%.
Earnings Estimates Revisions
Earnings estimate revisions is what the Zacks Rank is all about.
Estimates are moving higher for OptimizeRX (OPRX - Free Report) .
The full year 2025 has increased from $0.51 to $0.54 over the last 60 days.
2026 has increased from $0.66 to $0.68 over the same time period.
Growth
There is good growth projected for OptimizeRX (OPRX - Free Report) . This fiscal year analysts are expecting $103M in revenue which would be good for 12.7% topline growth.
Next fiscal year, the consensus is calling for $117M and that would be good for 12.6%.
Valuation
The forward PE for OptimizeRX (OPRX - Free Report) is just above the market multiple at 23x. The price to book is low at 2x and that should keep the value oriented investors interested in the stock. Price to sales comes in at 2.5x.
Margins have increased from -3.1% to -0.2% over the last two quarters so investors are expecting that metric to be positive when the company reports again.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Bull Of The Day: OptimizeRX (OPRX)
OptimizeRX (OPRX - Free Report) is a Zacks Rank #1 (Strong Buy) that has an F for Value and an A for Growth. The company runs a health solutions platform that helps physicians and patients better afford and comply with their medicines and healthcare products. The company is expected to report earnings on 8/7, so now is a great time to take a look at this small cap company. Let’s learn more about why this stock is the Bull of the Day.
Description
OptimizeRx Corporation provides consumer and physician platforms to help patients better afford and comply with their medicines and healthcare products. It offers pharmaceutical and healthcare companies effective ways to expand patient awareness, access and adherence to their brands. The Company offers marketing and advertising solutions by connecting patients, physicians, and pharmaceutical manufacturers through its consumer Websites. OptimizeRx Corporation is based in Rochester, Michigan.
Earnings History
When I look at a stock, the first thing I do is look to see if the company is beating the number. This tells me right away where the market’s expectations have been for the company and how management has communicated to the market. A stock that consistently beats has management communicating expectations to Wall Street that can be achieved. That is what you want to see.
OptimizeRX (OPRX - Free Report) has posted four consecutive beats of the Zacks Consensus Estimate. The takeaway from the earnings history is that the company has an average positive earnings surprise of 105% over the last year.
The most recent earnings print saw the company post $0.08 when the consensus was at -$0.11. That 19 cent beat translates into a positive earnings surprise of 172%.
Earnings Estimates Revisions
Earnings estimate revisions is what the Zacks Rank is all about.
Estimates are moving higher for OptimizeRX (OPRX - Free Report) .
The full year 2025 has increased from $0.51 to $0.54 over the last 60 days.
2026 has increased from $0.66 to $0.68 over the same time period.
Growth
There is good growth projected for OptimizeRX (OPRX - Free Report) . This fiscal year analysts are expecting $103M in revenue which would be good for 12.7% topline growth.
Next fiscal year, the consensus is calling for $117M and that would be good for 12.6%.
Valuation
The forward PE for OptimizeRX (OPRX - Free Report) is just above the market multiple at 23x. The price to book is low at 2x and that should keep the value oriented investors interested in the stock. Price to sales comes in at 2.5x.
Margins have increased from -3.1% to -0.2% over the last two quarters so investors are expecting that metric to be positive when the company reports again.